Navigation Links
UNC awarded Cancer Genome Atlas grant
Date:9/30/2009

CHAPEL HILL, N.C. The University of North Carolina at Chapel Hill is one of twelve centers announced today by President Obama as part of an unprecedented large-scale, collaborative effort by the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI) to systematically characterize the genomic changes that occur in cancer.

The Cancer Genome Atlas Grant (TCGA) is a five-year award, expected to bring $13 to $20 million to UNC, which puts scientists from the university's Lineberger Comprehensive Cancer Center and their collaborators across campus at the center of a major push to provide a deeper, more systematic understanding of the mechanisms responsible for the uncontrolled growth of cancer cells and their spread throughout the body.

According to the NHGRI, the genomic information generated by the project could fuel rapid advances in cancer research including new ways to categorize tumors, new therapeutic targets, and methods that allow clinical trials to focus on patients who are most likely to respond to specific treatments. The project aims to develop a comprehensive catalog of the many genetic and genomic changes that occur in cancers including chromosomal changes, gene expression differences, DNA mutations, and epigenomic changes (changes that happen to DNA but do not change the underlying hereditary information).

"This project represents one of the most ambitious and challenging human genetics efforts to date, only rivaled by its predecessor, the Human Genome Project," said Dr. Charles Perou, associate professor of genetics, and pathology & laboratory medicine.

"The TCGA project takes a comprehensive approach to the study of human cancers and applies multiple cutting-edge technologies to the same large set of tumors. The real power of this project is in the integration of these different genetic data types into a common framework that should provide a much more complete picture of why a tumor is a tumor," he added.

"We are enormously excited to be one of only a handful of institutions selected for this tremendously important cancer project," said Dr. H. Shelton Earp, Director of UNC Lineberger Comprehensive Cancer Center.

"Cancer genetics has been a key area for University Cancer Research investment, allowing us to diversify the technologic base needed for this project. This phase of The Cancer Genome Atlas will yield many new cancer discoveries that may change the face of clinical cancer care in the near future."

UNC's specific focus is to characterize what genes are being expressed, and not expressed, in each tumor type studied. Using a methodology called "gene expression profiling", scientists get a very powerful look at a given tumor and can precisely determine what genes are "on" and what genes are "off". Cancers are typically caused by some genes being inappropriately on, and other genes being inappropriately off, thus being able to look at all genes at once and determine which are on is critical to a better understanding of tumor biology.

Project co-director Neil Hayes, notes that the laboratory science is specifically designed to benefit patients as quickly as possible. "Our participation is recognition that UNC has a community of cutting-edge researchers, particularly in our 'bench to bedside' approach and as one of only a few NCI-designated Comprehensive Cancer Centers included in the funding. Just as we balance our days between patient care and science, the leadership at NCI and NHGRI is asking us to keep this project grounded in benefits to patients. I can't imagine a more important leadership role, and we take this charge very seriously," he said.


'/>"/>

Contact: Ellen de Graffenreid
edegraff@med.unc.edu
919-962-3405
University of North Carolina School of Medicine
Source:Eurekalert

Related biology news :

1. 2 neuroscientists from Cold Spring Harbor Laboratory awarded transformative NIH grants
2. IOF-AMGEN Health Professional Awareness Grants awarded at Beijing conference
3. Prestigious $4.9 million NIH grant awarded to Case Western Reserve for colon cancer research
4. UA awarded $4.35 million to study Earths critical zone
5. Researcher awarded $1.2 million grant to study centrosomes and cilia
6. Barrow scientist awarded $400,000 grant to study cell associated with intuition and autism
7. IGC scientist awarded prestigious European Research Council Starting grant
8. LSUHSCs Bazan awarded ARRA grant to preserve vision
9. UTSA psychologist awarded $1 million for memory research
10. LSUHSCs Kolls awarded $1.8 million to improve vaccine strategies for P. carinii pneumonia
11. NYU Langone Medical Center awarded NIH grants totaling $1,560,000
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/2/2017)... , Feb. 2, 2017   TapImmune, ... clinical-stage immuno-oncology company specializing in the development of ... the treatment of cancer and metastatic disease, announced ... and GMP manufacturing of a second clinical lot ... targeting folate receptor alpha. The manufactured vaccine product ...
(Date:2/1/2017)... 2017 IDTechEx Research, a leading provider of ... the availability of a new report, Sensors for Robotics: Technologies, ... Reading ... ... Source: IDTechEx Report "Sensors for Robotics: Technologies, Markets and Forecasts 2017-2027: ...
(Date:1/26/2017)... PANAMA CITY , Jan. 26, 2017  Crossmatch, ... today unveiled a new solution aimed at combatting fraud, ... The solution was introduced at the Action on Disaster ... a key meeting point for UN agencies and foreign ... Fraud, waste and abuse are a largely ...
Breaking Biology News(10 mins):
(Date:2/27/2017)... Pharmaceuticals, Inc. ("InMed") (CSE: IN; OTCQB: IMLFF), reported today that ... total of 10,672,750 common share purchase warrants have been exercised ... the exercise of these warrants totalled $1,387,458 and 10,672,750 common ... ... expression of confidence by our warrant holders. This infusion of ...
(Date:2/27/2017)... HAMILTON, Bermuda , Feb. 27, 2017 /PRNewswire/ ... ) and SELLAS Life Sciences Group , ... immunotherapies, today announced that Advaxis has granted SELLAS ... agent using Advaxis, proprietary Lm -based antigen ... peptide antigen mixture (galinpepimut-S). Advaxis, ...
(Date:2/27/2017)... , ... February 27, 2017 , ... The Catalyst ... a few in the Midwest offering premix services and private label organic services. , ... laying hens, according Jos Zamzow, chief operating officer of Dynamite Marketing, which owns the ...
(Date:2/24/2017)... MA (PRWEB) , ... February 24, 2017 , ... ... replacement (TDR) procedures can be safely completed in an ambulatory surgery center (ASC) ... fusion (ACDF) procedures and previous two-year TDR studies. , Jake Lubinski, president ...
Breaking Biology Technology: